BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 10093499)

  • 1. Angiotensin II receptors-antagonists, molecular biology, and signal transduction.
    Jagadeesh G
    Indian J Exp Biol; 1998 Dec; 36(12):1171-94. PubMed ID: 10093499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
    Aulakh GK; Sodhi RK; Singh M
    Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure].
    Sandmann S; Unger T
    Drugs; 2002; 62 Spec No 1():43-52. PubMed ID: 12036388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE; McKinnie JJ; Greenberg SS; Giles TD
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II--receptor subtypes characterization and pathophysiological implications.
    Gulati K; Lall SB
    Indian J Exp Biol; 1996 Feb; 34(2):91-7. PubMed ID: 8641721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor.
    Murphy TJ; Alexander RW; Griendling KK; Runge MS; Bernstein KE
    Nature; 1991 May; 351(6323):233-6. PubMed ID: 2041570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to explain the differences between renin angiotensin system modulators.
    Levy BI
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):134S-141S. PubMed ID: 16125050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [AT1 angiotensin receptor inhibition as a new therapeutic possibility].
    Hunyady L; Nagy L
    Orv Hetil; 1997 Oct; 138(41):2583-90. PubMed ID: 9411327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The renin-angiotensin-aldosterone system and fibrinolysis.
    Felmeden DC; Lip GY
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):240-4. PubMed ID: 11881031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
    Johnston CI
    Blood Press Suppl; 2000; 1():9-13. PubMed ID: 11059629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
    Carnovali M
    Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Historical development of losartan (DuP 753) and angiotensin II receptor subtypes.
    Wong PC; Timmermans PB
    Blood Press Suppl; 1996; 3():11-4. PubMed ID: 8973760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical pharmacology of angiotensin II antagonists].
    Ambrosioni E; Bacchelli S
    Cardiologia; 1994 Dec; 39(12 Suppl 1):401-4. PubMed ID: 7634304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
    Leary AC; MacDonald TM
    Int J Clin Pract; 1998 Oct; 52(7):475-81. PubMed ID: 10622089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.